Population Pharmacokinetics and Exposure-response Analysis of Durvalumab in Patients with Limited-stage Small-cell Lung Cancer in the Phase 3 ADRIATIC Study.
AAPS JSep 28, 2026 (epub)
Hong Su, Becky Jiajia Zhao, Yu Fu et al.
✦ AI-curated · Sources linked
In 30 seconds
The ADRIATIC study evaluated the population pharmacokinetics and exposure-response relationships of durvalumab in patients with limited-stage small-cell lung cancer (LS-SCLC). This Phase III randomized controlled trial found that at a dose of 1500 mg IV Q4W, durvalumab demonstrated a flat exposure-response relationship for both efficacy and safety endpoints, indicating no need for dose adjustments.
Key findings
- Typical parameter estimates for durvalumab included clearance of 0.273 L/day and volumes of distribution of 3.49 L and 2.35 L.
- Kaplan Meier plots suggested a plateaued relationship between durvalumab exposure and progression-free survival (PFS) or overall survival (OS).
- No significant prognostic factors for OS or PFS were identified from exposure metrics.
- A flat exposure-response relationship was observed for Grade 3+ treatment-related adverse events.
Why it matters
Understanding the pharmacokinetics and exposure-response relationships of durvalumab can help clinicians optimize treatment strategies for patients with LS-SCLC, ensuring effective management without unnecessary dose adjustments.